These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 10423607

  • 1. The prescription Drug User Fee Act of 1992 and the new drug development process.
    Kaitin KI.
    Am J Ther; 1997; 4(5-6):167-72. PubMed ID: 10423607
    [Abstract] [Full Text] [Related]

  • 2. The Prescription Drug User Fee Act of 1992. A 5-year experiment for industry and the FDA.
    Shulman SR, Kaitin KI.
    Pharmacoeconomics; 1996 Feb; 9(2):121-33. PubMed ID: 10160091
    [Abstract] [Full Text] [Related]

  • 3. Economic Impacts of the Generic Drug User Fee Act Fee Structure.
    Dong K, Boehm G, Zheng Q.
    Value Health; 2017 Jun; 20(6):792-798. PubMed ID: 28577697
    [Abstract] [Full Text] [Related]

  • 4. Approval times for new drugs: does the source of funding for FDA staff matter?
    Carpenter D, Chernew M, Smith DG, Fendrick AM.
    Health Aff (Millwood); 2003 Jun; Suppl Web Exclusives():W3-618-24. PubMed ID: 15506165
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The new drug approvals of 1993, 1994, and 1995: trends in drug development.
    Kaitin KI, Manocchia M.
    Am J Ther; 1997 Jan; 4(1):46-54. PubMed ID: 10423591
    [Abstract] [Full Text] [Related]

  • 12. Explaining reductions in FDA drug review times: PDUFA matters.
    Olson MK.
    Health Aff (Millwood); 2003 Jan; Suppl Web Exclusives():W4-S1-W4-S2. PubMed ID: 15506166
    [Abstract] [Full Text] [Related]

  • 13. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates.
    Berndt ER, Gottschalk AH, Philipson TJ, Strobeck MW.
    Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239
    [Abstract] [Full Text] [Related]

  • 14. Drug-review deadlines and safety problems.
    Carpenter D, Zucker EJ, Avorn J.
    N Engl J Med; 2008 Mar 27; 358(13):1354-61. PubMed ID: 18367738
    [Abstract] [Full Text] [Related]

  • 15. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
    DiMasi JA.
    Clin Ther; 2013 Jun 27; 35(6):808-18. PubMed ID: 23726388
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. FDA user fees approved.
    Clin Pharm; 1993 Jan 27; 12(1):3. PubMed ID: 8428431
    [No Abstract] [Full Text] [Related]

  • 19. Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs.
    Wilmoth DR.
    Health Econ; 2015 Dec 27; 24(12):1651-6. PubMed ID: 25753390
    [Abstract] [Full Text] [Related]

  • 20. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule.
    Food and Drug Administration, HHS.
    Fed Regist; 2008 Jul 10; 73(133):39588-611. PubMed ID: 18850675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.